Business Wire

X2nSat Selects LeoSat’s Laser-Enabled Data Network to Support Healthcare Communications

Share

LeoSat Enterprises, which is launching a constellation of 108 low-earth-orbit communications satellites that will provide the fastest, most secure and widest coverage data network in the world, today announced that X2nSat, the highly reliable satellite solutions provider, has selected LeoSat to support new infrastructure solutions for the ever-expanding needs of the healthcare industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190506005302/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New Satellite Constellation providing the first business backbone in space for Enterprise Data. (Photo: Business Wire)

X2nSat currently offers SatBlue, a proprietary line of voice and data communications solutions tailored for the healthcare industry (including data and internet redundancy, emergency response trailers and telemedicine capabilities), which allows hospitals and medical office buildings to customize communications solutions based on their existing infrastructure, and to expand when the need for additional capabilities arises.

Whether it is through telemedicine, video conferencing or transferring medical records via broadband, hospitals and medical facilities have unique needs when it comes to communications. Network reliability and scalability are key for both service continuity and disaster recovery plans. With healthcare, a back-up communications system not only keeps the business running, it can help save lives.

With data volumes exploding, the increasing demand to move large quantities of data quickly and securely around the world is fast outpacing the infrastructure needed to carry it. LeoSat has developed a unique system architecture – a space-based MPLS network - providing Gigabits of secure connectivity with lower latencies than fiber, opening-up new possibilities for Healthcare providers looking for scalable, flexible solutions for their expanding networks.

Garrett Hill, CEO of X2nSat, said: “Technology is crucial to Healthcare. With cloud computing and Big Data becoming more and more prominent, healthcare providers are seeking a reliable, disaster-resistant backbone for effective healthcare IT management. Satellite is the missing puzzle piece for the delivery of reliable communication and data connectivity. LeoSat’s unique high throughput, low latency and highly secure data communications network will enable us to offer new data and voice connectivity solutions and work closely with healthcare providers to create effective disaster preparedness plans”.

As part of the agreement, Hill receives a designated seat on LeoSat’s Customer Technical Advisory Committee, an institution created to structure collaboration and exchange information surrounding the design, configuration, production, and launch of the LeoSat satellite constellation. Says Hill, “X2nSat’s Las Cruces, New Mexico Satellite Gateway has been designed and optimized for high-throughput satellites, and X2nSat is looking forward to collaborating with LeoSat on how best to deliver the latest generation of solutions to our enterprise customers”.

Michael Abad-Santos, SVP Americas, LeoSat said: “Satellite is often seen as a last resort for enterprise data communications. But with capabilities beyond existing satellite and fiber, including transmission speeds of 5.2 gigabits per second and latency of 20 milliseconds, LeoSat’s infrastructure is what data communications has been waiting for – a game-changing service which realizes the synergies of both worlds to re-define connectivity in terms of capacity, latency, security, efficiency and coverage. Using our unique backbone in space we can provide fast and ultra-secure point-to-point data connections to and from anywhere on earth without the need for any terrestrial landings”.

LeoSat is backed by leading satellite operators SKY Perfect JSAT and Hispasat, and the system is being developed in conjunction with Thales Alenia Space, a company with unmatched expertise in designing and manufacturing low earth orbit constellations. The high-throughput satellites (HTS) in the constellation will form a mesh network interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones, thus creating a paradigm shift in the use of satellites for data connectivity – rather than a gap filler or last resort where no terrestrial alternative is available. LeoSat has already secured over 2 Billion USD in pre-launch customer agreements and was recently granted a license by the FCC to operate its network in the U.S. ENDS

NOTE TO EDITORS

To find out more about LeoSat, come along to one of the panels at Sat2019. To arrange an interview, please contact Melanie Dickie. Email: Melanie@leosat.com or call +31 6 14 22 97 62.

  • Monday 6 May, 1.30pm: An Introduction to HTS and Other Acronyms (Unveiled Theater)
  • Wednesday 8 May, 3pm: Integrating LEO Constellations Into Teleport Services (Room 147)
  • Thursday 9 May, 10:45am: Executive Round Table – LEO/MEO Systems (Room 146)

About LeoSat Enterprises

LeoSat Enterprises was established to leverage the latest developments in satellite communications technologies to develop and launch a new low-earth-orbit satellite constellation which will provide the first commercially available, business grade, extremely high-speed and secure data service worldwide. With up to 108 low-earth-orbit communications satellites in the constellation LeoSat is the first company to have all the High Throughput Satellites (HTS) in the constellation interconnected through laser links, creating an optical backbone in space which is about 1.5 times faster than terrestrial fiber backbones and without the need for any terrestrial touchpoints. This unique set of features enables LeoSat to provide instant infrastructure from anywhere to everywhere which is fast, secure and reliable.

Based in Washington DC, LeoSat is currently working with Thales Alenia Space for the low-earth-orbit constellation of Ka-band communications satellites. Once operational, the constellation will provide high-speed, low-latency and highly secure communications and bandwidth for business operations in the telecom backhaul, Energy, Maritime, Government and international business markets. Launch of the constellation is expected in 2020. www.leosat.com

About X2nSat

Founded in 1996, X2nSat provides highly reliable wireless network and communications solutions, with a commitment to making the world, business and life better with reliable communication anytime, anywhere. Working “above the cloud,” X2nSat offers the robust services of a large telecommunications company with the personalized customer care of a specialty organization, and is a leading provider of satellite technology to enterprise organizations in healthcare, utilities, and other industries. For more information, visit www.X2nSat.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Melanie Dickie
VP Marketing & Communications, LeoSat Enterprises
Tel: +31 6 14 22 97 62
Email: melanie@leosat.com

Media Contact for X2nSat:
Jena Blazer, Director of Sales and Marketing
+1.707.664.5712
jena.blazer@x2nsat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye